PMC:4631427 / 24519-24898 JSONTXT

{"project":"TEST0","denotations":[{"id":"26604803-164-170-1382697","span":{"begin":164,"end":166},"obj":"[\"16275379\"]"}],"text":"In 2005, Enrique et al from Spain performed a randomized, double-blind placebo-controlled study for sublingual immunotherapy (SLIT) in adults with hazelnut allergy.72 During the final assessment, half of the patients in the treatment group were able to reach the highest dose of hazelnut (20 g) on OFC compared with only 9% in placebo group. Long-term efficacy was not evaluated."}

{"project":"2_test","denotations":[{"id":"26604803-16275379-55579392","span":{"begin":164,"end":166},"obj":"16275379"}],"text":"In 2005, Enrique et al from Spain performed a randomized, double-blind placebo-controlled study for sublingual immunotherapy (SLIT) in adults with hazelnut allergy.72 During the final assessment, half of the patients in the treatment group were able to reach the highest dose of hazelnut (20 g) on OFC compared with only 9% in placebo group. Long-term efficacy was not evaluated."}